Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride. It exports its products to approximately 85 countries, including the United States, the European Union, and internationally. The company is based in Jingmen, China.
Stock data | 2024 | Change |
---|---|---|
Price | $0.4067394466648777 | N/A |
Market Cap | $2.01B | N/A |
Shares Outstanding | 4.94B | N/A |
Employees | 2.10K | N/A |
Valuation | 2024 | Change |
---|---|---|
P/FCF | 0.60 | N/A |
Dividends | 2024 | Change |
---|---|---|
Dividend Yield | 9.53% | N/A |
Dividend per share | 0.0388 | N/A |
Growth | 2024 | Change |
---|---|---|
CAPEX | -17.20M | N/A |
Earnings | 2024 | Change |
---|---|---|
Free Cash Flow | $3.34B | N/A |